Heart muscle gel for children with hlhs during stage ii surgery
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a gel that is injected directly into the heart muscle during the Stage II Glenn operation for children with Hypoplastic Left Heart Syndrome. The goal is to see if the gel is safe and can help the heart function better after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must have Hypoplastic Left Heart Syndrome (HLHS), a heart condition where the left side of the heart is underdeveloped.
- Child must be scheduled for a Stage II Glenn operation, a heart surgery to improve blood flow, within the first year of life.
- Child must not have needed a mechanical heart or lung support machine (like ECMO or a ventricular assist device) in the past 5 days.
- Child must not have a history of cancer or tumors.
- Child must not have a bleeding or clotting disorder, or certain abnormal lab test results that could increase surgical risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an infusion of heart stem/progenitor cells can improve outcomes for children with a single working heart chamber (single ventricle) who are scheduled for the next surgical stage (Glenn or Fontan). It may help the heart function after surgery, but participation depends on several heart, lung, brain, and overall health safety criteria.
This trial focuses on improving care for babies born with certain complex heart conditions where only one pumping chamber works. It is meant for babies (including unborn babies) who are planned to have the Norwood procedure, which is a common early surgery.
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
This trial studies whether a newer “tissue-engineered” blood vessel graft is safe and works well in children who need a specific heart surgery connection outside the heart. It may help by offering a new type of graft, but your team will screen for size and medical factors first.
This trial tests a small heart pump (the Jarvik 2015) designed to support children with severe heart failure who are waiting for a heart transplant. The pump helps the heart pump blood, which may improve strength and organ function while they wait.
This study tests a custom-made patch for repairing the main artery (aorta) during a Norwood procedure in newborns. The patch is designed from each baby's own CT scan to fit better, which may improve surgery outcomes.
Hear when a new Hypoplastic Left Heart Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.